Monte Rosa Therapeutics, Inc.

What they do

Monte Rosa discovers and develops molecular glue degraders, small molecules that direct the body's ubiquitin-proteasome system to eliminate disease-causing proteins. Its proprietary discovery engine, QuEEN, supports programs including the NEK7-directed MGD MRT-8102, the GSPT1-directed MGD MRT-2359, and CDK2 and CCNE1 MGDs. The VAV1-directed MGD MRT-6160 is licensed to Novartis, which conducts its development. The company is headquartered in Boston, Massachusetts.

Revenue drivers

• Novartis collaboration (MRT-6160 and discovery programs) — Novartis holds a global exclusive development and commercialization license for the VAV1-directed MGD MRT-6160; collaboration payments are the company's main revenue source, with total revenue of $123.7M in 2025 versus $75.6M in 2024.
• Roche collaboration — An agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. covers discovery programs; it is cited alongside the Novartis agreement as a source of potential collaboration revenue.
• Proprietary pipeline (MRT-8102, MRT-2359, CDK2/CCNE1) — These wholly owned or company-led programs generate no product revenue; they are funded by collaboration receipts and the balance sheet.

Recent performance

Second quarter 2026 revenue was $9.0M, up from $4.2M in Q1 2026 but below the $12.8M reported in Q3 2025 and above the $2.8M in Q4 2025. Full-year revenue rose from $75.6M in 2024 to $123.7M in 2025, while net loss narrowed from $72.7M in 2024 to $38.6M in 2025. Operating cash flow was negative $22.8M in 2025 after positive $42.0M in 2024, reflecting the timing of collaboration receipts. At June 30, 2026, the company reported $90.1M of cash and equivalents, total assets of $691.2M, total liabilities of $203.9M and shareholder equity of $487.3M.

Strategy

The company is advancing MRT-8102 across inflammatory and cardiometabolic indications: GFORCE-1 in elevated CVD risk completed enrollment, with a readout expected in H2 2026, and Phase 2 studies planned in atherosclerotic and cardiometabolic disease in H2 2026, gout flares in Q4 2026/Q1 2027, and hidradenitis suppurativa in H1 2027. The MODeFIRe-1 Phase 2 study of MRT-2359 with apalutamide in mCRPC patients with AR mutations has been activated. Novartis activated a Phase 2a/b trial of MRT-6160 (DDY391) in Sjogren's disease under the global license. Management states cash, cash equivalents, restricted cash and marketable securities of $626.0M should fund operations into 2029.

Risks

• Early-stage clinical pipeline — Lead programs such as MRT-8102 and MRT-2359 are in Phase 1/Phase 2 and have not demonstrated regulatory approvability, so failure or delay in any trial would remove a major source of future value.
• Dependence on collaborators — MRT-6160 is developed by Novartis, and Roche is a partner on discovery programs, so milestone, payment and development timelines are largely outside Monte Rosa's control.
• Revenue concentration and variability — Annual revenue has come from collaboration arrangements, falling to $2.8M in Q4 2025 from $12.8M in Q3 2025, and operating cash flow swung from $42.0M positive in 2024 to $22.8M negative in 2025.
• Novel technology and platform risk — MGDs target proteins historically considered undruggable or inadequately drugged, and the company must maintain and expand its MGD library and QuEEN discovery engine to sustain the pipeline.

Outlook

Management describes a catalyst-rich second half of 2026, led by GFORCE-1 data for MRT-8102 across multiple dose levels and inflammatory and cardiometabolic biomarkers including calprotectin, pathologic cytokines and CRP. Over the next 9 to 12 months it expects to initiate three MRT-8102 Phase 2 studies, including GFORCE-2 later in 2026 and GEMINI-1 in gout. It also expects first patients to enroll imminently in MODeFIRe-1 and plans updates from the initial Phase 1/2 MRT-2359 arm in advanced CRPC by the end of the year. Management states its $626.0M of cash, cash equivalents, restricted cash and marketable securities is expected to support operations into 2029.